Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CDNA +8.6% (guidance; also to divest Lab Products business), PPG +6.2% (guidance; also price increases across product lines; completes Ozark Materials acquisition), JBHT +2%, MRSH +1.8%, PEP +1.3%, USB +1.1%
Other news:
- ANL +19.3% (entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of ~$150.0 mln)
- MGTX +8.8% (three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1; entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire all interests in bota-vec for the treatment of XLRP)
- TII +8.5% (extends Kilbourne Graphite mineralization, advances germanium and the 2026 multi-commodity exploration strategy)
- TLSA +8% (Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function)
- VOYG +7.4% (selected by NASA for private astronaut mission)
- NUCL +7.1% (provides first quarter 2026 corporate update)
- EVTL +7.1% (announced its successful completion of a two-way piloted transition flight under the direct oversight of the UK Civil Aviation Authority)
- BMM +6.2% (drilling activities at its Nussir Copper-Gold-Silver Project)
- TTE +3.3% (reports Q1 main indicators)
- UUUU +2.3% (appoints Ross Bhappu as CEO, succeeding Mark Chalmers)
- SVRA +2.2% (FDA extends review period for the molgramostim BLA)
- EQH +2.1% (Equitable Holdings, in consultation with Corebridge Financial (CRBG), is exploring undertaking repurchases of shares of its common stock prior to closing of the parties' pending merger)
- ALGT +2% (achieves key regulatory milestone with DOT approval)
- NKTX +1.7% (agreement with FDA on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials)
- ECX +1.7% (appoints Lone Fønss Schrøder as chairperson)
- ZIM +1.5% (CEO to step down)